SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Krensavage Asset Management, LLC

CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582

Reported Value
$289M
Q1 2021
Positions
12
Filings on Record
32
2019–present window
Filed
May 18, 2021
original filing

Summary

Krensavage Asset Management, LLC reported $289M in U.S.-listed holdings across 12 positions for Q1 2021.

Its largest position, ENTA, represents 14.7% of the portfolio.

Compared with Q4 2020, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+4.9%
vs prior filed quarter
Top-10 Concentration
+99.7%
share of reported value
Largest Position
+14.7%
Enanta Pharmaceuticals
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $370MQ1 ’19Q2 ’19: $308MQ3 ’19: $260MQ4 ’19: $293MQ1 ’20: $311MQ1 ’20Q2 ’20: $368MQ3 ’20: $314MQ4 ’20: $342MQ1 ’21: $289MQ1 ’21Q2 ’21: $295MQ3 ’21: $319MQ4 ’21: $288MQ1 ’22: $290MQ1 ’22Q2 ’22: $302MQ3 ’22: $314MQ4 ’22: $324MQ1 ’23: $329MQ1 ’23Q2 ’23: $316MQ3 ’23: $272MQ4 ’23: $282MQ1 ’24: $226MQ1 ’24Q2 ’24: $218MQ3 ’24: $178MQ4 ’24: $169MQ1 ’25: $181MQ1 ’25Q2 ’25: $189MQ3 ’25: $235MQ4 ’25: $283MQ1 ’26: $256MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 86.0%Other: 14.0%
  • Common Stock · 86.0% · $249M
  • Other · 14.0% · $40M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NEXTCURE INCNEW+30.6K30.6K+$306,000$306,000
NEXTCURE INCSOLD OUT−30.3K0−$330,000$0
ALXNALEXION PHARMACEUTICALS INCTRIMMED−357.4K6.9K−$56M$1M
ANABANAPTYSBIO INCTRIMMED−84.8K25.7K−$2M$554,000
UTHRUNITED THERAPEUTICS CORPTRIMMED−73.1K249.4K−$7M$42M
TARO PHARMACEUTICAL INDUSHELD−6.0K547.6K−$261,000$40M
REGNREGENERON PHARMACEUTICALSHELD+49882.7K−$584,000$39M
ENTAENANTA PHARMACEUTICALS INCHELD+4.0K862.8K+$6M$43M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ENTAENANTA PHARMACEUTICALS INChistory →COM14.73%$43M862.8K
2UTHRUNITED THERAPEUTICS CORPhistory →COM14.44%$42M249.4K
3TARO PHARMACEUTICAL INDUSCOM13.98%$40M547.6K
4REGNREGENERON PHARMACEUTICALShistory →COM13.54%$39M82.7K
5BIIBBIOGEN INChistory →COM13.41%$39M138.5K
6MCKMCKESSON CORPhistory →COM11.32%$33M167.6K
7ALKSALKERMES PLChistory →COM10.52%$30M1.63M
8SURGALIGN HOLDINGS INCCOM4.87%$14M6.45M
9INVACARE CORPCOM2.52%$7M908.2K
10ALXNALEXION PHARMACEUTICALS INCCOM0.37%$1M6.9K
11ANABANAPTYSBIO INCCOM0.19%$554,00025.7K
12NEXTCURE INCCOM0.11%$306,00030.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$256M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$283M18Feb 18, 202613F-HRchanges · EDGAR ↗
Q3 2025$235M17Nov 17, 202513F-HRchanges · EDGAR ↗
Q2 2025$189M15Aug 15, 202513F-HRchanges · EDGAR ↗
Q1 2025$181M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$169M12Feb 18, 2025RESTATEMENTchanges · EDGAR ↗
Q3 2024$178M13Nov 15, 202413F-HRchanges · EDGAR ↗
Q2 2024$218M13Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$226M12May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$282M12Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$272M12Nov 15, 202313F-HRchanges · EDGAR ↗
Q2 2023$316M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$329M12May 16, 202313F-HRchanges · EDGAR ↗
Q4 2022$324M12Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$314M14Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M14Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$290M13May 17, 202213F-HRchanges · EDGAR ↗
Q4 2021$288M10Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$319M13Nov 16, 202113F-HRchanges · EDGAR ↗
Q2 2021$295M13Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$289M12May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$342M12Feb 17, 202113F-HRchanges · EDGAR ↗
Q3 2020$314M11Dec 8, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$368M11Aug 20, 2020RESTATEMENTchanges · EDGAR ↗
Q1 2020$311M13May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$293M12Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$260M10Nov 15, 201913F-HRchanges · EDGAR ↗
Q2 2019$308M10Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$370M12May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.